Inicio breadcum Nota


Ventajas de la Fluvoxamina: Un ISRS con mecanismo de acción triple

Sistema Nervioso Central Video

Ventajas de la Fluvoxamina: Un Inhibidor Selectivo de la Serotonina que ofrece ventajas en los pacientes con depresión, ansiedad y Insomnio.


1.Stahl SM. Selectivity of SSRls: individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract. 2004;8(suppl 1):3-10.
2. Kam PCA and Chang GWM. Selective serotonin reuptake inhibitors – Pharmacology and clinical implications in anaesthesia and critical care medicine. Anaethesia.1997;52:982-988.
3. Hindmarch | and Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol. 2010;25(3):193-200.
4. Hashimoto K, Fujita Y, lyo M. Phencyclidine-Induced Cognitive Deficits in Mice are Improved by Subsequent Subchronic Administration of Fluvoxamine: Role of Sigma-1 Receptors. Neuropsychopharmacology.
5. Bobrov A, Krasnoslobodtseva L and Mutnykh E. Effects of Fluvoxamine on Cognitive Function in Outpatients with Depression in Remission: Results of an Open-Label Pilot Study. J Psychiatry. 2017;20:5
6. Hartter S, Wang X, Weigmann H, et al. Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin. J Clin Psychopharmacol. 2001;21(2):167-174.
7. Sunami E, Usada K, Nishiyama Y, et al. A preliminary study of fluvoxamine maleate on depressive state and serum melatonin levels in patients after cerebral infarction. Intern Med. 2012,51(10):1187-1193.
8. Serretti A and Chiesa A. Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis. J Clin Psychopharmacol. 2009;29(3):259-266.
9. Buchberger R and Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry. 2002;35(3):101-108.